Denosumab and Mortality in a Real-World Setting: A Comparative Study
Authors' conclusion
Dmab in women and oral BPs were associated with lower post-fracture mortality than no treatment. However, Dmab users had generally higher mortality than oral BP users in those without fractures.
Study context
- Population
- Sax Institute's 45 and Up Study, a prospective population-based cohort linked to hospital admissions and medication recordssource cohort
- Participants
- 267,357 participants
- Exposure
- DMAB vs no treatment and vs oral bisphosphonates (BPs) and zoledronic acid
- Outcome
- All-cause mortality
Methodological detailsnew-user cohort design, propensity-score matching, sex-specific pairwise multivariable Cox models
- New-user cohort design
- Propensity-score matching
- Sex-specific pairwise multivariable Cox models
Main finding
As reported in the abstract
Hazard ratio (95% CI)
Dmabvs No treatmentwomen, fracture cohort
0.52(0.36–0.72)
Oral BPsvs No treatmentwomen, fracture cohort
0.56(0.42–0.77)
Oral BPsvs No treatmentmen, fracture cohort
0.56(0.40–0.78)
Dmabvs Oral BPswomen, no-fracture cohort
1.49(1.13–1.98)
Dmabvs Oral BPsmen, no-fracture cohort
2.74(1.82–4.11)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| All-cause mortality, no-fracture cohortDmab (no-fracture cohort)vs Oral BPs (no-fracture cohort)Women · propensity-score matched | 1.49 (1.13–1.98) | |
| All-cause mortality, no-fracture cohortDmab (no-fracture cohort)vs Oral BPs (no-fracture cohort)Men · propensity-score matched | 2.74 (1.82–4.11) | |
| 0.20.5125Hazard ratio (log scale) |
All-cause mortality, no-fracture cohort
- Denosumab (Dmab) had similar mortality to Zol
Original publication
Denosumab and Mortality in a Real-World Setting: A Comparative Study. J Bone Miner Res. Published 1 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →